Patents by Inventor Yanran Ai

Yanran Ai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20260098041
    Abstract: The present application is concerned with tricyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 26, 2025
    Publication date: April 9, 2026
    Applicant: Incyte Corporation
    Inventors: Le ZHAO, Yanran AI, Marc DELLER, Javier FELICIANO, Ananda GHOSH, Leslie McQUIRTER, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
    Publication number: 20250388553
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: August 22, 2025
    Publication date: December 25, 2025
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • BICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250333419
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 30, 2024
    Publication date: October 30, 2025
    Applicant: Incyte Corporation
    Inventors: Joe Barbosa, Yanran Ai, Marc Deller, Balu D. Dherange, Ananda Ghosh, Joe Glenn, JR., Leslie McQuirter, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20250333420
    Abstract: The present application is concerned with bicyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 13, 2024
    Publication date: October 30, 2025
    Applicant: INCYTE CORPORATION
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Lixin SHAO, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20250320212
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: November 27, 2024
    Publication date: October 16, 2025
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Aminopyrazine derivatives as PI3K-? inhibitors
    Patent number: 12421197
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: September 23, 2025
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS
    Publication number: 20250270218
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Yehao QIU, Cooper TAYLOR, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS
    Publication number: 20250270217
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran AI, Joe BARBOSA, Huan CHEN, Marc DELLER, Balu D. DHERANGE, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Yong LI, Leslie McQUIRTER, Yehao QIU, Stacey SHEPARD, Cooper TAYLOR, Xiaozhao WANG, Eddy Yue, Guofeng ZHANG, Le ZHAO, Zhitong ZHENG
  • BICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250236622
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 30, 2024
    Publication date: July 24, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran Ai, Joe Barbosa, Marc Deller, Balu D. Dherange, Ananda Ghosh, Joe Glenn, JR., Leslie McQuirter, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250215006
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 14, 2024
    Publication date: July 3, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran Ai, Joe Barbosa, Ananda Ghosh, Marc D. Deller, Joe Glenn, JR., Leslie McQuirter, Yehao Qiu, Lixin Shao, Stacey Shepard, Cooper Taylor, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20250122170
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 31, 2024
    Publication date: April 17, 2025
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue
  • Kinase Inhibitors
    Publication number: 20250092044
    Abstract: The present application provides heterocyclic compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 20, 2025
    Inventors: Zhitong Zheng, Yanran Ai, David M. Burns, Kai Liu, Cooper Ashley Taylor, Eddy W. Yue
  • Kinase Inhibitors and Degraders
    Publication number: 20250092043
    Abstract: The present application provides heterocyclic compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 20, 2025
    Inventors: David M. Burns, Yanran Ai, Kai Liu, Cooper Ashley Taylor, Eddy W. Yue, Zhitong Zheng
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 12187725
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: August 24, 2023
    Date of Patent: January 7, 2025
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Yu Bai, Joseph Barbosa, Hao Feng, Leah C. Konkol, Xun Liu, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Bicyclic Ureas As Kinase Inhibitors
    Publication number: 20240317744
    Abstract: The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 12, 2024
    Publication date: September 26, 2024
    Inventors: Xin Li, Oleg Vechorkin, Yanran Ai, Onur Atasoylu, Hang Thi Dang, Brent Douty, Chunhong He, Peng He, Michael Liang, Minh Nguyen, Evan Styduhar, Anlai Wang, Xiaozhao Wang, Hai Fen Ye, Eddy W. Yue, Ke Zhang, Peng Zhao
  • Heterocyclic Compounds As Kinase Inhibitors
    Publication number: 20240300948
    Abstract: The present application provides heterocyclic compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: February 22, 2024
    Publication date: September 12, 2024
    Inventors: Charles Cole, Yanran Ai, Eddy W. Yue
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 12084430
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Eddy W. Yue
  • Heterocyclic derivatives as PI3K inhibitors
    Patent number: 12006320
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20240150354
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: May 9, 2024
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 11780840
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue